NCT01929603 - Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

November 30, 2016

Conditions

Solid Tumours

Interventions

PROCEDURE

Pharmacokinetic sampling

Blood sampling to measure olaparib, rifampicin and 4β-hydroxycholesterol

DRUG

Rifampicin

Rifampicin (CYP inducer) 600mg taken once daily from Day 5 to Day 14 (Part A)

DRUG

Olaparib tablet dosing

Olaparib 300mg tablet taken on Days 1 and 14 (Part A). Part B dosing is 300mg olaparib bi-daily

Trial Locations (5)

Research Site, Edegem

Research Site, Ghent

Research Site, Wilrijk

Research Site, Amsterdam

Research Site, Maastricht